Combined Anti-CD20/Anti-CD38 Therapy in Posttransplant Focal Segmental Glomerulosclerosis Recurrence: A Retrospective, International, Multicenter Study

16 patients with biopsy-proven post-transplant FSGS recurrence, most resistant to rituximab and plasma exchange, treated with rituximab plus daratumumab or daratumumab alone. Complete remission in 5 and partial in 11; 13 still in remission at a median 11 months, with plasma exchange discontinued in all but 3. Significant decline in IgM but not IgG.